Faculty

Fabrice Lucien-Matteoni, Ph.D.

Clinical Studies

Integration of PSMA PET imaging and Extracellular Vesicle-Based Tumor Monitoring for Biochemically Recurrent Prostate Cancer Rochester, Minn.
The purpose of this study is to develop an inexpensive and non-invasive blood test that can help refine the identification of patients with PSMA-positive metastatic lesions following biochemical recurrence.
Profiling of Tumor-Derived Extracellular Vesicles and Circulating CD8+-T cells for Prediction of Response to Immunotherapy in Metastatic Renal Cell Carcinoma (RCCEV) Rochester, Minn.
Immunotherapy has revolutionized the therapeutic landscape for patients with metastatic RCC and response rates are higher than previously observed with tyrosine kinase inhibitors. Despite this, there is a growing need for molecular markers that can help identify patients who will benefit from immunotherapy, especially in the landscape of multiple available regimens, potential toxicities and financial burden. In this study, we propose to use blood biopsies to study tumor-derived extracellular vesicles (tdEVs) to assess disease burden, monitor response to therapy, and to predict earlier disease progression. In addition to tdEVs, these samples will also be analyzed for other biomarkers (circulating immune cells) to assess if they can be used to inform on tumor-immune cell interactions in real-time and potentially identify responders to immunotherapy.

Integration of PSMA PET imaging and Extracellular Vesicle-Based Tumor Monitoring for Biochemically Recurrent Prostate Cancer Scottsdale/Phoenix, Ariz.
The purpose of this study is to develop an inexpensive and non-invasive blood test that can help refine the identification of patients with PSMA-positive metastatic lesions following biochemical recurrence.

Ex-vivo Surfaceomics of Patient-Derived Tumors for Next-Generation Cancer Immunotherapies (EVST) Rochester, Minn.
In this study, we propose to use a combination of cell-surface capture and mass spectrometry on patient tumors to identify tumor-associated cell-surface proteins that are targetable with next-generation immunotherapies. These therapeutic antibodies and their derivatives have transformed the therapeutic landscape of cancer patients. Only 20% of cell-surface proteins have been investigated so far for drug development. Untargeted proteomics has been the gold standard to identify tumor-associated proteins. However, it suffers from low sensitivity for cell-surface proteins. Cytosolic proteins are much more abundant and soluble than cell-surface proteins which results in limited resolution of the entire cell-surface proteome.
Prospective Collection of Blood and Urine of Healthy Individuals for Liquid Biopsy Research (HDEV) Rochester, Minn.
The overall objective of this study is to collect blood and urine specimens from healthy donors under standardized protocols for liquid biopsy research.